ReviewBritish journal of cancer2026
Using biomaterial-based 3D in vitro cancer models to solve current clinical problems.
Review in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Recent advances in the field of biomaterials show promise in developing pre-clinical models that could elucidate new and innovative treatments for cancer. Both cellular and acellular components can drive cancer formation, progression, and metastasis. Biomaterial-based 3D in vitro models can mimic both these cellular and acellular components. Highly tuneable and biocompatible materials such as hydrogels provide a scaffold for in vitro investigations, mimicking the tumour extracellular matrix structure, upon which cancer cells and additional cellular components can be seeded. Such models have already shown good mimicry of the tumour microenvironment, demonstrating a platform that can be used for drug screening, investigation of treatment response, and a model for the mechanisms of cancer progression. The limitations of current preclinical models include long development times, false-positive drug screening results in 2D cell culture models, and high cost of animal models. This review aims to show the role of biomaterial-based models in addressing existing clinical problems by bridging the gap between current research outcomes and their potential clinical impact.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.